2ry Analysis of a RCT | Metformin linked to 41% reduction in long COVID incidence in outpatient treatment

Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial – The Lancet Infectious Diseases

News Release: Study shows metformin lowers the risk of getting long COVID – University of Minnesota Medical School

Commentary: Expert reaction to study on Metformin after testing positive for SARS-CoV-2 and risk of developing long COVID – Science Media Centre

Commentary on Twitter

These data not persuasive. There are 6 different arms. 3 drugs. This is not the primary endpoint. No adjustment for multiple testing.

Even USFDA would not accept these data for regulatory approval, and they are basically working for Pharma at this pthttps://t.co/FZoxo9shtG

— Vinay Prasad MD MPH (@VPrasadMDMPH) June 9, 2023